

# Acasti Pharma Inc

13:35 27 Dec 2019

## Acasti Pharma shares on the move, expects to report TRILOGY 1 results of CaPre trial in January

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) shares regained ground on Friday after announcing earlier this week it expects to report next month its topline results for the TRILOGY 1 Phase 3 trial of lead drug CaPre, which treats severe hypertriglyceridemia.

The reporting of Trilogy 1 was postponed due to an unexpected delay in data processing and transfer from the central testing laboratory to the statistical consultants for independent and external validation, according to a statement.

Shares of the pharmaceutical firm grew 13.2% in Canada at C\$3.25 on Friday afternoon.

### READ: Research firm Encode Ideas starts coverage on biotech Acasti Pharma

Laval, Quebec-based Acasti said it regrets the delay due to factors outside its control, and now anticipates to report topline results in January 2020.

The company also benefitted from research firm B Riley maintaining a Buy rating on the stock and a C\$8 price target. Analyst Mayank Mamtani wrote that the delay was likely "inconsequential" to the TRILOGY 1 results.

As requested by the Investment Industry Regulatory Organization of Canada (IIROC), due to market volatility, the company said that it has no material update to provide at this time beyond the above timing update and independent and external validation exercise that is underway.

Implementation of the Trilogy 2 Study remains on track, and the company continues to expect the last patient to complete their final visit in early January 2020, and expects to report topline results in Trilogy 2 towards the end of January 2020.

Topline results will include a readout of the primary endpoint, which is intended to show CaPre's overall impact on lowering triglycerides (TGs) after 12 weeks compared to placebo.

Safety and tolerability, serious adverse effects (AE) rate, and any discontinuation due to AEs will also be reported. Other important secondary endpoints such as non-HDL cholesterol, HDL cholesterol, and VLDL may now also be reported with the topline results.

As previously disclosed, subgroup analyses of certain key secondary and exploratory markers (HbA1c) will be dependent on combining results from both studies and would be expected sometime later in the first quarter of 2020.

CaPre is a highly purified omega-3 phospholipid concentrate stemming from krill oil to treat hypertriglyceridemia, or elevated levels of fat in the blood, which can lead to increased risk of cardiovascular disease and pancreatitis.

**Price:** 0.57

**Market Cap:** \$51.42 m

### 1 Year Share Price Graph



March 2019 September 2019 March 2020

### Share Information

**Code:** ACST

**Listing:** TSX-V

<b>52 week</b>	<b>High</b>	<b>Low</b>
	4.05	0.35

**Sector:** Pharma & Biotech

**Website:** [www.acastipharma.com](http://www.acastipharma.com)

### Company Synopsis:

*Acasti is a biopharmaceutical innovator focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. Omega-3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

In other company news, Acasti also provided an update on its previously adopted at-the-market program (ATM Program) for the month of November 2019, as required pursuant to the policies of the TSX Venture Exchange.

Acasti said it issued an aggregate of 2,628,263 common shares over the NASDAQ Stock Market for total gross proceeds of US\$5,693,057.27.

The ATM shares were sold at prevailing market prices which ranged from US\$2.05 per share to US\$2.27 per share.

On Friday Acasti shares lost 7.6% in the US at US2.49.

--Updated with share price and analyst note--

Contact the author: [patrick@proactiveinvestors.com](mailto:patrick@proactiveinvestors.com)

Follow him on Twitter @PatrickMGraham

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

#### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).